These pages report on the use of Mri for breast cancer screening, the association between hormone replacement therapy and breast cancer incidence, the link between human papillomavirus (HPv) and head and neck cancers, and the use of radiation therapy to prevent lung cancer from spreading. They also report on effective new targeted therapies for cancers that have been historically difficult to treat, such as liver cancer and kidney cancer, among many others. a total of 24 advances are featured in this year's report.
Clinical Cancer Advances is an independent annual review of the top advances in cancer treatment, prevention, and screening across all cancer types, conducted by the american society of Clinical Oncology (asCO).
Over the past three decades, investment in clinical cancer research, prevention, and screening has reduced cancer incidence and death rates, increased survival rates, and significantly reduced the symptoms and side effects of cancer and its treatment. The latest statistics show that cancer death rates decreased by 2. This report documents 24 of the most significant advances on the front lines of cancer research over the past year, including six that the editors of this report consider major advances. This year, major advances can be grouped into two categories:
Prevention and Screening:
z studies on screening and preventing cancer from forming and spreading, including: research and guidelines on the appropriate use of magnetic resonance imaging for breast cancer screening; studies identifying a link between declines in use of hormone replacement therapy and breast cancer incidence; research linking HPv infection and head and neck cancers; and a study of radiation therapy to prevent the spread of lung cancer to the brain.
Targeted Therapies:
z studies of effective new targeted therapies for hard-to-treat cancers such as liver cancer and kidney cancer.
While much progress has been made, cancer still takes a tremendous toll, and new, more effective prevention and treatment strategies are urgently needed. The united states is currently in the midst of the longest sustained period of flat government funding for cancer research in the country's history. When adjusted for inflation, the budget of the national Cancer institute (nCi) has actually declined 12 percent since 2004. Without additional support, the opportunity to build on the extraordinary progress to date will be lost or delayed.
SuMMARy of findingS
Following is a summary of the major clinical research advances in 2007:
PRevenTion And SCReening AdvAnCeS several studies helped expand knowledge about how to best screen for certain cancers, and how to prevent cancer from both forming and spreading.
Role of MRi for Breast Cancer Screening
The use of magnetic resonance imaging (Mri) to detect breast cancer has generated significant debate. While some studies have suggested that Mri may be better able to detect some breast cancers compared with mammography, the cost, high rate of false-positives, and inconsistent standards for performing Mris have made broad use impractical. This year, new guidelines and findings from several studies provided additional guidance about how Mri should be used for breast imaging:
The american Cancer society released z guidelines stating for the first time that evidence supported routine Mri screening for women at high risk of developing the diseasethose with a 20 percent or greater risk of developing breast cancer over their lifetime, including women with strong family histories of breast cancer, certain genetic mutations, and other known risk factors. a study suggested that patients recently z diagnosed with cancer in one breast may benefit from Mri of the other breast to increase the chance of detecting additional cancers that may have been missed by mammography or clinical examination, since women who have had cancer in one breast are at increased risk for developing cancer in the other. a second study found that Mri is significantly z more sensitive than mammography for detecting ductal carcinoma in situ (a noninvasive, precancerous condition in which abnormal cells are found in the lining of a breast duct). Mri was particularly effective at finding those tumors that are more likely to be biologically aggressive and have the potential to turn into invasive breast cancer.
it is important to note that despite the benefits of breast Mris for women in high-risk groups, Mri is not yet recommended for the majority of women as a screening tool for breast cancer because of the cost, lack of standards, and high rate of falsepositives, which can lead to unnecessary biopsies. Mammograms are still considered the best screening tool for women who are at normal risk for breast cancer.
Role of hPv infection in head and neck Cancers
Two studies shed light on the role that human papillomavirus (HPv, the virus present in virtually all cervical cancers) plays in the development of head and neck cancers. The studies suggest a possible role for the recently approved HPv vaccine in preventing head and neck cancers.
The first study found that oral HPv infection z is strongly associated with certain types of head and neck cancer, regardless of whether patients used tobacco and alcohol (established risk factors for these types of cancer). The researchers found that one of the strains of HPv most commonly associated with cervical cancer was detected in 72 percent of oral cancer tumors.
The second study evaluated the link between z HPv infection, treatment response, and survival outcome for patients with certain head and neck cancers. it found that patients with HPv-positive tumors may have a better prognosis than patients with HPv-negative tumors. Patients with the virus had a lower risk that their disease would spread and a reduced risk of death. researchers believe it is possible that the HPv infection causes cancers that are biologically different from other cancers. decreasing use of hormone Replacement Therapy linked to declines in Breast Cancer Cases Two studies this year reported that the recent significant reduction in breast cancer incidence appears to be associated with the declining use of hormone replacement therapy (HrT) in menopausal women. The use of HrT declined beginning in 2002, following a report from the national institutes of Health-sponsored Women's Health initiative that linked the use of estrogen plus progestin during and after menopause with a number of adverse effects, including an increased risk for invasive breast cancer. While other factors that could have played a role in the decreased incidence (e.g., recent declines in mammography screening rates and changes in diet) could not be completely ruled out as contributors, the association with HrT was strong.
Preventive Radiation Therapy improves Survival for Patients with Small Cell lung Cancer researchers reported for the first time that radiation therapy to the head for patients with advanced small cell lung cancer cuts the risk that the cancer will spread to the brain by about twothirds, and as a result extends patients' lives. in this study, radiation prevented the deterioration of physical and psychological functioning that can occur when cancer spreads to the brain. Previous studies have showed that radiation therapy to the head can extend survival in patients with earlier stage small cell lung cancer, but this was the first
ABouT ThiS RePoRT
The American Society of Clinical Oncology-the leading medical society representing more than 25,000 oncologists and other professionals worldwide who care for people with cancer-has developed this report to demonstrate the important progress being made in clinical cancer research and to highlight emerging trends in the field.
The report is also intended to fill a gap in cancer literature. It is the only published report to highlight the major advances in clinical cancer research and care each year, and it is written for everyone with an interest in cancer care: the general public, cancer patients and organizations, policymakers, oncologists, and other medical professionals.
This report, now it its third year, was developed under the guidance of a 21-person editorial board made up of leading oncologists and other cancer specialists, including specialty editors for each of the disease-specific and issue-specific sections. The editors reviewed research published in peer-reviewed scientific journals and the early results of research presented at major scientific meetings over a one-year period (October 2006 -September 2007 . Only studies that significantly altered the way a cancer is understood or had an important impact on patient care were included. Research in each section is divided into "major advances" and "other notable research," depending on the impact of the advance on patient care and survival. in myeloma patients whose disease had recurred and was progressing despite prior treatment with other therapies. The researchers found that 58 percent of patients responded to lenalidomide and bortezomib, including 6 percent who had complete remission. The median duration of remission was six months, with some patients experiencing remission for up to two-and-a-half years.
Bortezomib, which was approved by the Fda in 2003, interferes with the ability of myeloma cells to break down and dispose of certain proteins, a process they need to grow and spread. lenalidomide, approved by the Fda for myeloma in 2006, disrupts the way tumor cells interact with surrounding tissue in the bone marrow.
BReAST CAnCeR
Over the past few decades, improvements in early detection and the development of more effective treatments have led to significant declines in breast cancer deaths and improved outlook for women living with the disease. increasingly, breast cancer is being treated as a group of diseases rather than as a single disease. The molecular characteristics of each person's tumor cells are taken into account when treatment options are considered. For example, identifying whether specific hormone receptors are present in a patient's cancer cells can help determine whether therapies targeted at those receptors will help an individual patient. improved prognostic methods also help determine how aggressive a patient's treatment should be.
This year, magnetic resonance imaging (Mri) was recommended for breast cancer screening in specific groups of patients. in addition, a decline in breast cancer incidence rates was linked to a reduction in the use of hormone replacement therapy. another large trial looked at the best way to deliver radiation therapy to patients after they have had surgery for early-stage disease.
MAJoR AdvAnCeS MRi for Breast Cancer detection
The use of Mri to detect breast cancer has generated significant debate. While some studies have suggested that Mri may be better able to detect some breast cancers compared with mammography, the cost, high rate of false-positives, and inconsistent standards for performing Mris have limited its potential usefulness. This year, findings from several studies led to new guidelines about the use of Mri for breast imaging:
The Conventional radiation therapy for women with early breast cancer is typically given at a consistent dose, delivered in 25 installments ("fractions"), five days a week over a period of five weeks. Physicians hypothesized that it may be possible to reduce the overall radiation dose and the treatment period without compromising the safety or effectiveness of therapy. This trial comprised two different studies that looked at different variations in radiation dose. after an average follow-up of five to six years, the incidence of local recurrence remained very low among all patients in both trials (3.4 percent of patients had local relapse with no significant difference between radiation regimens). 
CenTRAl neRvouS SySTeM CAnCeRS
Treating tumors of the central nervous system and the brain in particular represents a unique clinical challenge. although clinical trials over the past 25 years have evaluated a variety of drugs and treatment delivery systems, the prognosis for people with brain tumors has remained largely unchanged. This year a clinical trial showed for the first time that a combination of drugs shrinks gliomas, the most common form of brain cancer, which has been particularly difficult to treat. another study showed that radiation therapy can benefit elderly patients with glioblastoma. The study was the first to evaluate this combination, providing a new treatment option and enabling more patients to have their tumors surgically removed. Cetuximab is currently approved by the Fda as second-line or third-line therapy, meaning it is used to treat advanced colorectal cancer that has continued to grow despite previous therapy.
2 high-fat diets linked to Recurrence of Colon Cancer a large observational study of patients with stage iii colorectal cancer (cancer that has spread to the lymph nodes) found that some dietary patterns were linked to a higher risk of disease recurrence and death following surgery than others. The study was designed to evaluate the benefits of two forms of adjuvant chemotherapy (additional treatment given after the primary treatment for disease). Because both treatments resulted in identical outcomes, researchers were able to study the entire study population as a single group. The investigators compared the likelihood
gASTRoinTeSTinAl CAnCeRS
Gastrointestinal cancers include those of the esophagus, stomach, liver, pancreas, biliary tract, colon, rectum, and anus. The ability to effectively treat these cancers varies significantly. For example, while many colorectal cancers can be diagnosed in their early, more curable stages using colonoscopy, no such screening tests exist for less common cancers of the digestive tractsuch as those of the pancreas-which are often diagnosed when they are advanced and difficult to treat effectively. in 2007, research investigated the use of targeted terapies to treat a variety of gastrointestinal cancers. in addition, a large study found a link between diets high in fat and an increased risk of recurrence and death in patients with colorectal cancer that had spread to the lymph nodes.
MAJoR AdvAnCe Sorafenib improves Survival in liver Cancer
Primary liver cancer (cancer arising in the liver rather than spreading to the liver from other organs or sites) is the third leading cause of cancer death globally, often resulting in death within a year of diagnosis. in a significant advance in the treatment of the disease, a phase iii study found that patients who took the targeted therapy sorafenib (nexavar) for hepatocellular carcinoma (the most common type of liver tumor) lived about 44 percent longer compared with patients who did not receive the anti-cancer drug. sorafenib, a tablet that is taken orally, is currently approved by the Fda for treating a form of advanced kidney cancer, and is being evaluated in patients with other cancers.
in this study, patients who received sorafenib lived a median of 10.7 months compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group: 5.5 versus 2.8 months. 
geniTouRinARy CAnCeRS
Genitourinary cancers include cancers of the prostate, kidneys, testicles, and bladder/urethra. The most significant research finding this year identified a new potential treatment for kidney cancer. research showed that bevacizumab, a drug that has been approved by the Fda for the treatment of metastatic colorectal cancer and non-small cell lung cancer, was also effective against renal cell carcinoma. Historically, there have been very few effective treatments for renal cell carcinoma, the most common type of kidney cancer. in the past two years, however, three targeted therapies have proven effective in increasing survival and have received Fda approval-sorafenib, sunitinib, and temsirolimus.
MAJoR AdvAnCe
Bevacizumab for Renal Carcinoma a large multicenter study showed adding bevacizumab to interferon-α2a (an older kidney cancer drug) as a first-line treatment for advanced kidney cancer nearly doubles progression-free survival-the length of time during and after treatment that the cancer does not grow. This was the first randomized phase iii trial to confirm its activity in the first-line treatment of kidney cancer. in the study, patients with metastatic kidney cancer who had had surgery to remove their tumors were randomized to receive either bevacizumab or a placebo in addition to interferon. adding bevacizumab nearly doubled progressionfree survival, from 5.4 months to 10.2 months. The tumor response rate was 31 percent for the bevacizumab group versus 13 percent for the placebo group. about half of the women received eBrT after surgery and half did not. after a median follow-up of more than four years, neither overall survival nor likelihood of recurrence differed significantly between the two groups. However, the incidence of side effects in the radiation therapy group was nearly double that in the surgery group: 61 percent compared with 31 percent. The most common side effects were fatigue, diarrhea, and increased urinary frequency. 
heAd And neCK CAnCeRS
Cancers of the head and neck-those affecting the nose, mouth, throat, tongue, and larynx, as well as the thyroid gland-are usually treated with a combination of surgery, chemotherapy, and/or radiation therapy. in the past year, there were two major findings that explored the link between head and neck cancers and human papillomavirus (HPv), the virus that causes the majority of cervical cancer cases. in addition, targeted therapies showed promise for a number of different types of head and neck cancer. 
MAJoR AdvAnCe

Role of HPV Infection in Head and Neck Cancers
MAJoR AdvAnCe
Preventive Radiation Therapy decreases Brain Metastases, Prolongs Survival, for Patients with Advanced lung Cancer researchers reported for the first time that radiation therapy to the head given to patients who respond to chemotherapy for advanced small cell lung cancer cuts the risk that the cancer will spread to the brain by about two-thirds, and as a result extends patients' lives.
This is important because when cancer spreads to the brain, it leads to the deterioration of physical and psychological functioning. Previous studies showed that radiation therapy to the head can extend survival in patients with earlier stage small cell lung cancer, but this was the first study to evaluate the treatment in patients with advanced disease, who have an even higher risk of developing brain metastases. after one year, the radiation therapy group had significantly fewer brain metastases-causing symptoms (15 percent) than the control group (40 percent). Moreover, 27 percent of the patients in the radiation therapy group were alive after one year, compared with only 13 percent of patients who did not receive the treatment. PediATRiC CAnCeRS significant progress has been made over the past several decades in treating childhood cancer, with overall five-year survival now at nearly 80 percent, compared with 58 percent about 30 years ago. This is due, in part, to the fact that most childhood cancer patients are treated in clinical trials, where they have access to cutting-edge therapies, and are closely monitored.
However, long-term side effects of cancer treatment continue to be a problem. This year, a large international trial found that the intensity of treatment for the rare childhood cancer neuroblastoma can be greatly reduced, maintaining high survival rates while lowering major side effects such as organ damage and hearing loss.
another study looked at programs for improving childhood cancer treatment in low-and middleincome countries and found that relatively small monetary investments aimed at the specific needs of each country can improve the treatment of children with cancer.
noTABle ReSeARCh less intense Treatment for Children with Advanced neuroblastoma Achieves high Survival Rates neuroblastoma is a relatively rare pediatric cancer of the sympathetic nervous system that typically begins in one of the adrenal glands. although survival rates are generally high, the standard treatment can have long-lasting side effects, including kidney and heart damage and hearing loss.
a large phase iii clinical trial showed that infants and children with neuroblastoma can be treated with significantly less aggressive chemotherapy than has been typically used and still achieve high survival rates. The study was conducted by the Children's Oncology Group, a cooperative organization of physicians and institutions in the united states, Canada, australia, and new Zealand. Patients in the trial received fewer rounds of chemotherapy over a shorter total treatment time compared with the current standard treatment. in addition, researchers substituted cisplatin, one of the drugs normally used to treat neuroblastoma, with another drug called carboplatin.
Cisplatin has been associated with high rates of long-term side effects, especially hearing loss.
With an average follow-up time of three years, the overall survival rate for all patients in the study was 96 percent. While the study did not directly compare the less intense treatment with standard therapy, the survival rate was equivalent to or better than that seen in large studies of the standard treatment. in this study, major side effects to the heart, kidney, liver, and hearing were all less than 2 percent, significantly lower than those experienced with standard therapy. 
SARCoMA
sarcomas are rare tumors that can occur in any site of the human body, although about half occur in the limbs. There are more than 50 different types of soft tissue sarcomas, which originate in tissues such as fat, muscles, nerves, tendons, and blood and lymph vessels. sarcomas in the bone are known as osteosarcomas.
Because these tumors vary greatly in their tissue of origin, treatments also vary. about 15 percent of soft tissue sarcomas occur in the abdominal region, and many of those tumors are known as gastrointestinal stromal tumors (GisT). The targeted therapy imatinib is approved by the Fda for patients with inoperable or advanced GisT. in 2007, research indicated that the drug may also provide benefit when given as treatment after surgery to remove a single localized tumor (adjuvant therapy).
noTABle ReSeARCh imatinib increases Recurrence-free Survival in Patients with giST an nCi-sponsored study found that giving imatinib after surgery increases recurrencefree survival when administered following the complete removal of GisT lesions larger than three centimeters. after undergoing surgery, patients took imatinib or a placebo for one year and were screened frequently for tumor recurrence. at the end of the first year of treatment, 97 percent of patients in the imatinib group had not experienced recurrence, compared with 83 percent in the placebo group. The differences were most notable in patients with tumors larger than 10 centimeters. no differences in the overall survival rates were noted with this short follow-up. Based on the findings, the study was stopped early and any patients still taking placebo were offered imatinib. While these studies are promising, at this time aspirin is not recommended for colorectal cancer prevention for the general public because of its side effects, which include stomach pain, heart burn, nausea, and vomiting and possibly serious health risks including gastrointestinal bleeding.
reFerenCes
CAnCeR SuRvivoRShiP several studies in 2007 examined the long-term health problems of survivors of pediatric cancers. There are more than 10 million cancer survivors in the united states, and more than 250,000 of them were first diagnosed when they were under the age of 21. Today about 80 percent of children diagnosed with cancer will be alive at least five years after diagnosis, and many of them will be considered cured. However, cancer therapies such as chemotherapy and radiation-especially in children who are still growing at the time of treatment-can result in long-term health problems known as late effects. To study late effects, the nCi initiated the Childhood Cancer survivor study (CCss) in 1993. in the past year the group published several important studies on a variety of late effects, as did a multi-institutional european research group.
noTABle ReSeARCh long-term health Problems of Cancer Survivors
Two studies addressed the rates of long-term health problems in survivors of childhood cancer. a dutch study found that almost 75 percent of survivors had one or more health problems (including second cancers, coronary artery disease, lung problems, and endocrine disorder) and 24.6 percent had five or more health problems, after a median follow-up of 17 years. The most severe effects were found in survivors of bone tumors and the least severe were found in survivors of leukemia and Wilm's tumor. another study from CCss determined that 62.3 percent of survivors had at least one chronic health condition, while 27.5 percent had a severe or life-threatening condition, with an average time between cancer diagnosis and completion of the survey of 17.5 years.
1,2
Survivors of Childhood leukemia and Brain Tumors have elevated Stroke Risk a report from the CCss found that long-term survivors of childhood leukemia and brain tumors are at increased risk of stroke years after their cancer treatment has been completed, especially those who were treated with a particular type of radiation therapy. although the two diseases are very different, both leukemia and brain tumors require therapy of the central nervous system, usually with moderate or high-dose radiation therapy to the skull. For leukemia survivors, the rate of stroke was low-0.8 percent-but significantly higher than the control group of siblings who had not had cancer (0.2 percent). For brain tumor survivors, the rate of stroke was 3.4 percent, and as high as 6.5 percent for patients who had been treated with both cranial radiation and alkylating chemotherapy agents. 
